<DOC>
	<DOCNO>NCT00312104</DOCNO>
	<brief_summary>The trial conduct Europe Africa . The aim trial compare use insulin detemir twice daily combine mealtime insulin aspart insulin glargine daily combine mealtime insulin aspart . The trial involve patient Type 1 Diabetes .</brief_summary>
	<brief_title>Comparison Efficacy Safety Insulin Detemir Insulin Glargine Patients With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 1 diabetes least 12 month Current daily insulin dose 1.4 IU/kg BMI lesser equal 35 kg/m2 HbA1c great 7.5 % less equal 12.0 % In Austria , age 19 year Proliferate retinopathy maculopathy Recurrent major hypoglycaemia Any condition disease uncontrolled hypertension AIDS/HIV rule trial participation accord judgement investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>